Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116

As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.